Integrated CNS imaging for biodistribution, target engagement, and early clinical translation.
Perceptive Discovery delivers integrated CNS imaging and biomarker capabilities that bridge preclinical research with early clinical translation. Our teams combine advanced in vivo imaging with radiochemistry and target-validation assays to generate high-quality data that supports confident decision-making.
From biodistribution, occupancy, and pharmacodynamic studies to volumetric imaging and radioligand binding, we provide end-to-end support that accelerates neuroscience programs toward IND readiness.
We work across a broad range of CNS indications, including Alzheimer’s disease, Parkinson’s disease, depression, and neuroinflammation, enabling smarter discovery and translation for small molecules, biologics, and gene or RNA therapies.
Comprehensive In Vivo CNS Imaging Expertise
Track CNS delivery, half-life, and clearance of small molecules, antibodies, ASOs, and viral therapies using multi-modal imaging.
Quantify in vivo target engagement with saturation/competition binding and dose-occupancy modeling, supporting dose selection and IND readiness.
Measure neurotransmitter release, metabolism, and functional brain changes using PET, MRS, and autoradiography.
Assess treatment impact on brain morphology with high-resolution MRI, DTI, and segmentation- based volumetric analysis.
Perceptive Discovery integrates radiolabeling chemistry and molecular imaging to advance neuroscience programs
Our preclinical neuroscience CRO platform offers end-to-end support from tracer design through imaging execution
Purpose-Built Solutions for CNS Programs
